Business Context and Reporting Period
OraSure Technologies, Inc. filed this Form 8-K on June 1, 2005, to disclose a material definitive agreement entered into on that date. The company is a Delaware corporation headquartered in Bethlehem, Pennsylvania.
Key Financial Metrics
This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on forward-looking financial guidance triggered by a new commercial agreement.
Material Changes and New Agreements
On June 1, 2005, OraSure entered into an exclusive agreement with SSL International plc. Under this agreement:
- OraSure will manufacture and supply a cryosurgical wart removal product.
- SSL will distribute the product in the over-the-counter (OTC) footcare market in Europe, Australia, and New Zealand.
- The product will be sold under SSL's Scholl and Dr. Scholl trademarks.
- Initial retail availability is expected in the UK, France, Germany, Spain, and Italy in Fall 2005, with expansion to other non-American countries in early 2006.
Guidance, Outlook, and Management Commentary
Primarily due to the new agreement with SSL, management has updated its full-year 2005 financial outlook:
- Revenue: Anticipated to reach $70.0 million for the full year 2005.
- Net Income: Expected to be approximately $0.12 to $0.14 per share for the year.
The filing does not explicitly list new risks or contingencies beyond the standard implications of entering a new distribution partnership.
Key Facts for Investor Verification
- Verify the exclusivity terms and duration of the agreement with SSL International plc.
- Confirm the specific royalty or revenue-sharing structure between OraSure and SSL.
- Monitor the actual launch timeline in the UK, France, Germany, Spain, and Italy for Fall 2005.
- Compare the updated $70.0 million revenue guidance against prior year actuals or previous guidance to assess the magnitude of the change.